Editorial corrections and citation queries.

What we respond to

The editorial inbox is for corrections to factual claims on the site (a citation that does not support the quoted finding, a misstated dose value, a misattributed paper, a regulatory action mischaracterized), questions about the methodology used to assemble the dossier, and requests to clarify the inclusion or exclusion of a particular source.

If you believe a quantitative claim on this site does not match its cited source, please include the page name, the section heading, the specific claim, and a pointer to the source — DOI, PMID, NCT identifier, or stable URL. We treat citation errors as the most important class of correction and prioritize them in the inbox.

What we do not respond to

Medical advice is out of scope. This is a publisher's read of the research, not a clinical service, and the published CJC-1295 record would not support clinical advice in any case. Requests for dosing, individual treatment plans, side-effect assessments, drug-interaction queries, prescriptions, or any other clinical service are declined.

Vendor and compounding-pharmacy referrals are also out of scope. The site keeps no commercial relationship with any source of CJC-1295 or a related peptide and is in no position to recommend one; questions about where to buy any compound are declined.

Partnership and affiliate inquiries do not belong at this address either — the project is non-commercial in its current Phase 1 form.

Form

A simple contact form is provided below. Please use a working return address. Editorial correction queues are read weekly, not daily.